Clinical trial · Observational
The Human Papillomavirus (HPV) Transmission Pilot Study
NCT00823511CI-TRIAL-00016723completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This transmission pilot study is a prospective study to determine feasibility of enrolling female partners into an international transmission study. Companion study to MCC-13930.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Human Papillomavirus Infection | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Female Partners
- description
- Female partners of HIM Study participants
Primary outcomes (1)
- measure
- Proportion of men in the HIM study willing to invite their female partner to participate in partner study, proportion of female partners who: a) contact clinic for enrollment in study b) are eligible to participate in the study c) enroll in study.
- timeFrame
- 2 year accrual period
Secondary outcomes (1)
- measure
- Proportion of female partners who report being monogamous with the HIM partner, proportion of women that are both HPV sero negative and HPV DNA negative at enrollment, proportion of women who comply with study protocol over 2 years of follow up.
- timeFrame
- 2 years per participant
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Female partners of HIM Study participants * report no abnormal Pap smear during the past 6 months; * have not had a hysterectomy * have never been diagnosed with genital warts; * are not pregnant; * residents of southern Florida; * are not and have not been enrolled in an HPV vaccine trial; * willing to comply with scheduled visits every 6 months for 2 years. Exclusion Criteria: * Do not meet the Inclusion Criteria.
References
Publications (0)
Data not yet available
No reference posted for this study.